Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Christophe Weber will step down as CEO of Takeda next year, the company announced, following a dropoff in its share price ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025Management ViewChristophe Weber, CEO, announced his retirement ...

Julie Kim has been running Takeda’s US operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval.

The presentation of Japanese drugmaker Takeda’s latest financial results were presented Thursday, though they took a back ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

TOKYO -- Japan's Takeda Pharmaceutical announced on Thursday that CEO Christophe Weber will step down in June 2026 and be succeeded by current U.S. business head Julie Kim, who would become the ...

French-born Weber oversaw a reorientation that included the $62 billion acquisition of British rival Shire in 2019.